---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-051393"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:21:44.322723+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx Q1 revenue $8.0M (+96% YoY); US HF sales surge 132%; raises full-year guidance

## Summary
- Net loss of $11.4M ($0.55 per share) vs $10.0M ($0.49) in prior year quarter.
- U.S. heart failure revenue $6.8M (+132% YoY); active implanting centers grew to 122 (118% YoY).
- FY 2023 revenue guidance raised to $35.5M-$38.0M (prior $35M-$38M); gross margin guidance improved to 80%-83%.
- Q2 2023 revenue expected between $8.2M and $8.8M; operating expenses $76M-$80M for full year.
- Cash and equivalents $103.3M at quarter end; net cash used in ops and investing $10.5M.

## SEC filing metadata
- accession: 0001104659-23-051393
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/0001104659-23-051393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/tm2313916d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-051393
- JSON: https://secwatch.observer/filing/0001104659-23-051393.json
- Plain text: https://secwatch.observer/filing/0001104659-23-051393.txt

## Key facts
- Earnings Releases
  CVRx, Inc. reported the first quarter of 2023 results: revenue $8.0 million, net income Net loss was $11.4 million, or $0.55 per share, EPS $0.55 per share. Guidance reaffirmed.
  - Period: the first quarter of 2023
  - Revenue: $8.0 million
  - Net income: Net loss was $11.4 million, or $0.55 per share
  - EPS: $0.55 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: year quarter ● Active implanting centers in the U.S. grew to 122, an increase of 118% over the first quarter of 2022 ● Worldwide revenue for the first quarter of 2023 was $8.0 million, an increase of 96% over prior year quarter “I am thrilled with our first quarter performance, which demonstrated solid execution on multiple fronts. We were able to share the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/0001104659-23-051393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.